OptiZest V1.0

  • Research type

    Research Study

  • Full title

    Personalised Dose Optimisation of Zestril supported by the Digital Blood Pressure Diary in a Primary Care Environment in England: Pragmatic Observational Pilot Study for Remote Hypertension Treatment (OptiZest)

  • IRAS ID

    339990

  • Contact name

    Izabela Pilecka

  • Contact email

    izabela.pilecka@closedloopmedicine.com

  • Sponsor organisation

    Closed Loop Medicine Ltd

  • Clinicaltrials.gov Identifier

    TBC, www.clinicaltrials.gov

  • Duration of Study in the UK

    0 years, 5 months, 30 days

  • Research summary

    High blood pressure is a major health concern globally, causing a significant number of deaths and putting a strain on healthcare systems. We know that managing high blood pressure is crucial, especially considering its link to strokes and heart disease.
    Zestril, also known as lisinopril, is recommended for managing high blood pressure in England. It has been widely used for over 30 years and is considered one of the most frequently prescribed ACE inhibitors for managing high blood pressure. Our study focuses on individuals with high blood pressure who are eligible for taking Zestril as we would like to understand how people use Zestril in their daily lives. We will invite around 20-25 adult patients with high blood pressure who will check their blood pressure every morning and evening, recording the readings on a dedicated app. They will also track whether they have taken Zestril each day and note the dosage. We hope to make this process easier for both doctors and patients. Instead of checking blood pressure and adjusting the medication during in-person visits, we're exploring the use of remote monitoring.During these meetings, participants will discuss their blood pressure readings, adherence to Zestril, and any symptoms experienced in the past two weeks. Doctors will have the opportunity to make necessary adjustments to the Zestril dosage, with the goal of finding the optimal amount to better control blood pressure and maximise the effectiveness of Zestril.
    We think this can help patients take charge, reduce trips to the doctor, and give more accurate information about their blood pressure so that the Zestril dose can be just right for each person.
    We will also ask the participants to complete electronic questionnaires on their smartphone as we're also looking into how patients enjoy using the app and their experiences and adherence to the home blood pressure measuring and prescribed medication. This information will also help us understand how well patients can manage their high blood pressure with digital tools.
    Our goal is to make managing high blood pressure easier for patients and get better results. This study is just the beginning, and what we learn will help us create solutions that focus on patients in the future and improve how we use medicines like Zestril to lower high blood pressure.

  • REC name

    South West - Frenchay Research Ethics Committee

  • REC reference

    24/SW/0029

  • Date of REC Opinion

    29 Feb 2024

  • REC opinion

    Favourable Opinion